Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 28, 2014; 20(24): 7686-7695
Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7686
Table 2 Hepatitis B surface antigen predict virological response or hepatitis B e antigen loss/seroconversion during nucleos(t)ide analogues therapy
NAsTreatment durationCase numberCommentsRef.
Entecavir2 yr95HBeAg (+) patients: baseline HBsAg cutoff level of 9550 IU/mL yielded the highest predictive value in predicting the VR[31]
HBeAg (-) patients: baseline HBsAg or HBsAg decline levels could not predict VR
Entecavir2 yr101HBeAg (+) patients: HBsAg level at baseline was an independent factor of HBeAg loss/seroconversion[32]
HBsAg level < 3000 IU/mL at 3 mo of treatment was an independent factor for achieving VR
HBeAg (-) patients: HBsAg levels could not predict VR
EntecavirMore than 2 yr50Low baseline HBsAg levels were the most significant factor for achieving VR at year 2 of treatment[33]
Tenofovir6 yr104 HBV + HIVA higher level of HBsAg decline in patients with HBeAg loss compared to patients remaining HBeAg-positive (2.5 log IU/mL vs 1.8 log IU/mL, P < 0.001)[36]
Baseline HBsAg levels could not predict HBeAg loss